GSK Chief Names US as Top Market for New Drug Launches and Business Development

In an interview with the BBC from GSK's central London headquarters, Dame Emma emphasized that the US is "still the leading market in the world in terms of the launches of new drugs and vaccines," and alongside China, it is "the best market in the world to do business development." She also welcomed a new deal that will see the NHS pay more to help secure zero tariffs on shipping UK pharmaceuticals to America. The decision by GSK to invest heavily in the US comes as the UK pharmaceutical industry faces growing challenges, including pressure from the NHS to reduce drug prices and concerns over the impact of Brexit on the sector. Other major drug makers, such as Pfizer and AstraZeneca, have also pulled UK projects worth billions in recent years, citing similar frustrations. Industry experts say that the US offers a more favorable business environment for pharmaceutical companies, with a more streamlined regulatory process and a larger market for new drugs and vaccines. "The US is a critical market for GSK, and our investment plans reflect the company's commitment to delivering innovative medicines and vaccines to patients around the world," said a spokesperson for the company. The UK government has been working to address the concerns of the pharmaceutical industry, including the new deal with the NHS to secure zero tariffs on shipping UK pharmaceuticals to America. However, the industry remains cautious, with many companies continuing to invest in the US and other markets. As GSK's chief executive prepares to leave the company in January after eight years in charge, Dame Emma's comments on the US market are seen as a significant endorsement of the country's business environment. The company's investment plans are expected to create thousands of new jobs and drive economic growth in the US, further solidifying the country's position as a leading destination for foreign investment.